Gerald F. Cox

Vice President, Clinical Development

Back to Speakers

Dr. Gerry Cox is Vice President of Clinical Development for Rare Diseases at Sanofi Genzyme, Cambridge, MA. Since joining Genzyme in 2000, Dr. Cox has overseen the clinical development programs for several lysosomal storage disorders and was a major contributor to the regulatory approvals of two enzyme replacement therapies (Aldurazyme® for MPS I in 2003, and Elaprase® for MPS II in Japan in 2006) and one substrate replacement therapy (Cerdelga® for Gaucher disease type 1 in 2014). His group is also developing olipudase alfa, an enzyme replacement therapy for acid sphingomyelinase deficiency; neoGAA, a hyperphosphorylated 2nd generation enzyme replacement therapy for Pompe disease; and GZ/SAR402671, a novel CNS-penetrant glucosylceramide synthase inhibitor for Gaucher disease type 3. Dr. Cox graduated magna cum laude with a B.A. in biology from Harvard College in 1980 followed by an M.D. and Ph.D. in biology from the University of California at San Diego in 1989. He furthered his training at Boston Children’s Hospital by completing an internship and residency in pediatrics and clinical and research fellowships in genetics. Dr. Cox is a practicing physician who is board-certified in clinical, biochemical, and molecular genetics. Prior to Sanofi Genzyme, he was a full-time clinical geneticist at Boston Children’s Hospital, where he continues to see patients part-time and train fellows in the genetics clinic. He is an instructor in pediatrics at Harvard Medical School and a founding member of the scientific advisory boards for the Barth Syndrome Foundation and the Pediatric Cardiomyopathy Registry. Dr. Cox has authored more than 70 peer-reviewed publications, reviews, and book chapters. His clinical interests include inborn errors of metabolism and genetic causes of cardiomyopathy and eye diseases